全球 ADHD（注意力不足過動症）市場：依治療類型、年齡層、ADHD 亞型、地區、範圍和預測

ADHD（注意力不足過動症）市場規模及預測

2024年全球ADHD（注意力不足過動症）市場規模為237.4億美元，預計2031年將達到389.6億美元，2024年至2031年複合年增長率為7.05%。ADHD（注意力不足過動症）是一種神經發育障礙，其特徵是持續注意力不集中、過動和衝動，幹擾日常生活。雖然它主要影響兒童，但它可以持續到成年，影響生活的許多方面，包括學業表現、工作和人際關係。ADHD 管理介入措施包括藥物治療、行為治療和旨在提高注意力、組織能力和行為的教育支持。

隨著數位健康解決方案、個人化醫療的進步以及成人多動症研究的不斷增加，過動症治療的未來看起來充滿希望。這些進展預計將提高診斷準確性、治療效果和患者的整體治療結果。

ADHD（注意力不足過動症）的全球市場動態

塑造全球 ADHD（注意力不足過動症）市場的關鍵市場動態

主要市場推動因素

不斷提高的認識與支持：

對多動症的認識和宣傳不斷提高正在推動市場向前發展。例如，2024年8月，National Resource Center on ADHD發起了過動症意識月活動，顯著提高了公眾和專業人士對過動症的瞭解，從而提高了診斷和治療的採用率。

診斷技術的進步：

新的診斷工具和技術正在提高過動症診斷的準確性和效率。2024 年 7 月，FDA 批准了一款新的數位 ADHD 診斷應用程序，預計該應用程式將提供更方便、更準確的評估，從而促進市場成長。

擴大治療選擇：

新的和改進的藥物和治療方法是主要驅動力。2024 年 9 月，一家製藥公司將宣佈推出一種新的 ADHD 治療方法，可解決注意力不集中和過動症狀，預計將擴大治療選擇並推動市場成長。

政府措施和資金：

增加政府對過動症研究和治療的支持和資助正在推動市場成長。例如，2024 年 6 月，歐盟 (EU) 增加了對過動症研究計畫的資助，旨在改善治療策略和支持系統。

主要課題

偏見和誤解：

儘管人們的認識不斷提高，但對過動症的恥辱和誤解仍然存在。這可能促使不願尋求診斷和治療，從而影響為患者提供的護理和支持的整體品質。

昂貴的治療費用

：對於某些患者來說，過動症的藥物、治療和持續管理可能成本高昂，尤其是在健康保險有限的地區。這種財務障礙可能會限制獲得所需的治療和支援服務。

診斷標準的變化：

ADHD的診斷標準和治療方法因地區和醫療體系的不同而不同，這可能會導致診斷和治療的不一致。缺乏標準化可能會影響過動症治療的可靠性和患者的治療結果。

獲得特殊治療的機會有限：

專門治療過動症的醫療保健專業人員供不應求，特別是在農村和服務不足的地區。這種有限的訪問可能會阻礙及時的診斷和治療，影響患者的治療結果和整體市場的成長。

主要趨勢

提高認識和早期診斷：

隨著醫療保健專業人員和公眾對注意力不足過動症（ADHD）的認識不斷加深，診斷可以更早、更準確地進行。教育活動和診斷工具的進步促進了這一趨勢，從而提高了檢測率和治療率。

成人多動症診斷增加

隨著人們對其盛行率和影響的認識不斷提高，以前被忽視的成人多動症正在受到更多關注。診斷標準的改進和對成人多動症症狀的更好理解正在增加成人的診斷和個人化治療選擇。

整合數位健康解決方案：

行動應用程式和線上治療平台等數位健康技術的使用可以改善過動症的管理。這些工具可以改善患者獲得護理、即時監測和個人化介入的機會，從而獲得更好的結果。

擴大多模式治療方法：

將藥物療法和行為療法結合起來以提供更全面的多動症治療方法的趨勢日益明顯。這種多模式策略旨在解決疾病的多個方面，從而實現更有效的管理並提高患者的生活品質。

目錄

第1章簡介

• 市場定義
• 市場細分
• 調查方法

第 2 章執行摘要

• 主要發現
• 市場概況
• 市集亮點

第3章市場概況

• 市場規模和成長潛力
• 市場趨勢
• 市場驅動力
• 市場制約因素
• 市場機會
• 波特五力分析

第 4 章 ADHD（注意力不足過動症）市場：依治療類型

• 藥物治療
• 行為療法
• 綜合治療

第5章 ADHD（注意力不足過動症）市場：依年齡組

• 孩子
• 成人

第6章 ADHD（注意力不足過動症）市場：依 ADHD 亞型分類

• 注意力不集中主導型
• 過動衝動型
• 複合型

第7章區域分析

• 北美
• 美國
• 加拿大
• 墨西哥
• 歐洲
• 英國
• 德國
• 法國
• 義大利
• 亞太地區
• 中國
• 日本
• 印度
• 澳洲
• 拉丁美洲
• 巴西
• 阿根廷
• 智利
• 中東/非洲
• 南非
• 沙烏地阿拉伯
• 阿拉伯聯合酋長國

第8章市場動態

• 市場驅動力
• 市場制約因素
• 市場機會
• COVID-19 的市場影響

第9章 競爭格局

• 大公司
• 市場佔有率分析

第10章 公司簡介

• Eli Lilly and Company
• Pfizer Inc.
• Johnson & Johnson Services Inc.
• Lupin
• Novartis AG
• Takeda Pharmaceutical Company Limited
• Mallinckrodt plc.
• Purdue Pharma LP
• NEOS Therapeutics Inc.
• Supernus Pharmaceuticals Inc.

第11章市場前景與機遇

• 新興技術
• 未來市場趨勢
• 投資機會

第12章附錄

• 縮寫表
• 來源和參考文獻

Attention-Deficit Hyperactivity Disorder Market Size And Forecast

Global Attention Deficit Hyperactivity Disorder Market size was valued at USD 23.74 Billion in 2024 and is projected to reach USD 38.96 Billion by 2031 , growing at a CAGR of 7.05% from 2024 to 2031. Attention Deficit Hyperactivity Disorder (ADHD) is a neurodevelopmental disorder marked by persistent patterns of inattention, hyperactivity, and impulsivity that impair daily functioning. It primarily affects children, but it can persist into adulthood, affecting many aspects of life such as academic performance, work, and relationships. ADHD management interventions include medication, behavioral therapy, and educational support tailored to improve focus, organization, and behavior.

The future of ADHD treatment looks promising, thanks to advances in digital health solutions, personalized medicine, and increased research into adult ADHD. These developments are expected to improve diagnostic accuracy, treatment efficacy, and overall patient outcomes.

Global Attention Deficit Hyperactivity Disorder Market Dynamics

The key market dynamics that are shaping the global attention deficit hyperactivity disorder market include:

Key Market Drivers:

Increasing Awareness and Advocacy:

Growing awareness and advocacy efforts for ADHD are propelling the market forward. For instance, in August 2024, the National Resource Center on ADHD launched the ADHD Awareness Month campaign, which significantly increased public and professional understanding of the disorder, resulting in higher diagnosis rates and treatment adoption.

Advances in Diagnostic Technologies:

New diagnostic tools and technologies are improving the accuracy and efficiency of ADHD diagnosis. In July 2024, the FDA approved a new digital ADHD diagnostic app, promising more accessible and precise evaluations and expected to boost market growth.

Expansion of Treatment Options:

New and improved medications and therapies are a major driver. In September 2024, a pharmaceutical company announced the release of a novel ADHD medication that addresses both inattentive and hyperactive symptoms, broadening treatment options and driving market growth.

Government Initiatives and Funding:

Greater government support and funding for ADHD research and treatment are driving market growth. For instance, in June 2024, the European Union increased funding for ADHD research projects, with the goal of improving treatment strategies and support systems, which is expected to drive market growth in Europe and beyond.

Key Challenges:

Stigma and Misconceptions:

Despite growing awareness, stigma and misconceptions about ADHD remain. This can lead to reluctance to seek diagnosis and treatment, affecting the overall quality of care and support provided to patients.

High Cost of Treatment

: ADHD medications, therapies, and ongoing management can be prohibitively expensive for some patients, especially in areas with limited healthcare coverage. This financial barrier may limit access to necessary treatment and support services.

Variability in Diagnostic Criteria:

Differences in ADHD diagnostic criteria and practices between regions and healthcare systems can result in inconsistencies in diagnosis and treatment. This lack of standardization can have an impact on the reliability of ADHD treatment and patient outcomes.

Limited Access to Specialized Care:

There is a shortage of healthcare professionals who specialize in ADHD, especially in rural or underserved areas. This limited access can impede timely diagnosis and treatment, affecting patient outcomes and overall market growth.

Key Trends:

Increasing Awareness and Early Diagnosis:

As healthcare professionals and the general public become more aware of ADHD, diagnoses will be made earlier and more accurately. This trend is aided by educational campaigns and advances in diagnostic tools, which result in higher rates of detection and treatment.

Adult ADHD Diagnosis is Growing:

Adult ADHD, which was previously overlooked, is receiving more attention as awareness of its prevalence and impact grows. Improved diagnostic criteria and a better understanding of adult ADHD symptoms are leading to more diagnoses and personalized treatment options for adults.

Integration of Digital Health Solutions:

The use of digital health technologies, such as mobile apps and online therapy platforms, improves ADHD management. These tools improve patient access to treatment, real-time monitoring, and personalized interventions, resulting in better outcomes.

Expansion of Multimodal Treatment Approaches:

There is an increasing trend of combining medication with behavioral therapies to provide a more comprehensive approach to ADHD treatment. This multimodal strategy aims to address multiple aspects of the disorder, resulting in more effective management and higher patient quality of life.

What's inside a VMR industry report?

Our reports include actionable data and forward-looking analysis that help you craft pitches, create business plans, build presentations and write proposals.

Global Attention Deficit Hyperactivity Disorder Market Regional Analysis

Here is a more detailed regional analysis of the global attention deficit hyperactivity disorder market:

North America:

North America dominates the global attention deficit hyperactivity disorder (ADHD) market due to its well-established healthcare infrastructure, high rates of diagnosis, and wide range of treatment options. The region has a comprehensive support system that includes advanced medical facilities, research institutions, and a diverse range of ADHD medications and therapies. This robust healthcare ecosystem ensures that North America remains the leading market for ADHD treatment. For instance, in August 2024, the United States Food and Drug Administration (FDA) approved a new ADHD medication designed specifically for adults, cementing the region's position as a key market due to its strong regulatory framework and significant investment in ADHD research and treatment.

North America is also seeing rapid growth in the ADHD market. This growth is being driven by increased awareness of ADHD, improved diagnostic tools, and expanded access to both medication and behavioral therapies. In July 2024, the National Institute of Mental Health's (NIMH) increased funding for ADHD research are promoting advances in treatment and diagnostics. These efforts are not only improving care quality, but also contributing to the rapid growth of the region's ADHD market.

Asia Pacific:

Asia Pacific is the fastest-growing region in the global attention deficit hyperactivity disorder (ADHD) market, owing to rising awareness, improved diagnostic capabilities, and greater healthcare access. The rise in ADHD diagnosis in countries such as China, India, and Japan is being driven by increased public awareness and the adoption of international diagnostic guidelines. In June 2024, the Indian Ministry of Health launched a national awareness campaign for mental health disorders, including ADHD, which is expected to increase diagnosis rates and treatment accessibility in the region.

Furthermore, the Asia Pacific market is expanding rapidly due to advances in healthcare infrastructure and increased investment in mental health. For instance, in May 2024, the Chinese government announced a significant increase in funding for mental health services, including ADHD treatment, as part of a larger health reform agenda. This investment improves the availability of ADHD treatment options and promotes better diagnostic practices, thereby contributing to the region's rapid market growth.

Global Attention Deficit Hyperactivity Disorder Market: Segmentation Analysis

The Global Attention Deficit Hyperactivity Disorder Market is segmented on the basis of By Treatment Type, By Age Group, By Subtypes of ADHD, and By Geography.

Global Attention Deficit Hyperactivity Disorder Market, By Treatment Type

• Medication
• Behavioral Therapy
• Combined Therapy

Based on Treatment Type, the Global Attention Deficit Hyperactivity Disorder Market is segmented into Medication, Behavioral Therapy, and Combined Therapy. Medication dominates the global ADHD market because it is the primary and most widely used treatment option, providing effective symptom management for a large number of patients. The fastest-growing segment is Combined Therapy, which is driven by a growing recognition of the benefits of combining medication and behavioral therapy for more comprehensive ADHD management and better patient outcomes.

Global Attention Deficit Hyperactivity Disorder Market, By Age Group

• Children
• Adults

Based on Age Group, the Global Attention Deficit Hyperactivity Disorder Market is segmented into Children, Adults . Children are the dominant segment in the global ADHD market because the disorder is most commonly diagnosed during childhood, resulting in a greater number of cases and treatment options tailored to this age group. Adults are the fastest-growing segment, thanks to increased awareness of adult ADHD and improved diagnostic practices, which are detecting more cases of ADHD in previously undiagnosed adults.

Global Attention Deficit Hyperactivity Disorder Market, By Subtypes of ADHD

• Predominantly Inattentive Presentation
• Predominantly Hyperactive-Impulsive Presentation
• Combined Presentation

Based on Subtypes of ADHD, the Global Attention Deficit Hyperactivity Disorder Market is segmented into Predominantly Inattentive Presentation, Predominantly Hyperactive-Impulsive Presentation, and Combined Presentation. The global ADHD market is dominated by Combined Presentation, which includes a wide range of symptoms and is frequently diagnosed due to its comprehensive nature. Predominantly Inattentive Presentation is the fastest-growing segment, with increased awareness of inattentiveness and its consequences, resulting in more diagnoses and treatment options for people who primarily exhibit inattentive symptoms.

Global Attention Deficit Hyperactivity Disorder Market, By Geography

• North America
• Europe
• Asia Pacific
• Rest of the World
• On the basis of Geography, the Global Attention Deficit Hyperactivity Disorder Market are classified into North America, Europe, Asia Pacific, and Rest of World. North America dominates the global Attention Deficit Hyperactivity Disorder (ADHD) market, owing to high diagnosis rates, robust healthcare infrastructure, and significant investments in ADHD treatment and research. Asia Pacific is the fastest-growing region in this market, owing to rising awareness, higher diagnosis rates, and greater access to healthcare services, particularly in emerging economies.

Key Players

• The "Global Attention Deficit Hyperactivity Disorder Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are
• Eli Lilly and Company, Pfizer, Inc., Johnson & Johnson Services, Inc., Lupin, Novartis AG, Mallinckrodt plc., Purdue Pharma LP, NEOS Therapeutics, Inc., Supernus Pharmaceuticals, Inc.

Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with its product benchmarking and SWOT analysis. The competitive landscape section also includes key development strategies, market share, and market ranking analysis of the above-mentioned players globally.

• Global Attention Deficit Hyperactivity Disorder Market: Recent Developments
• In September 2024, BrainTech Solutions launched ADHDScan, an innovative digital app for remote ADHD diagnosis. This tool uses AI algorithms to provide accurate assessments, with the goal of improving access to diagnostic services, particularly in underserved areas.
• In July 2024, The World Health Organization (WHO) launched a global ADHD awareness campaign to emphasize the importance of early diagnosis and treatment. This initiative is expected to raise public awareness and lead to increased diagnosis rates worldwide.
• In June 2024, the Behavioral Health Alliance expanded its online therapy platform to include ADHD-specific programs. This expansion makes therapeutic options more accessible to people with ADHD, which helps the market grow.
• In April 2024, MedCore Pharmaceuticals launched a personalized ADHD treatment program tailoring medications and therapies based on genetic tests. This personalized approach aims to improve treatment outcomes and is expected to gain popularity in the market.

TABLE OF CONTENTS

1. Introduction

• Market Definition
• Market Segmentation
• Research Methodology

2. Executive Summary

• Key Findings
• Market Overview
• Market Highlights

3. Market Overview

• Market Size and Growth Potential
• Market Trends
• Market Drivers
• Market Restraints
• Market Opportunities
• Porter's Five Forces Analysis

4. Attention-Deficit Hyperactivity Disorder Market, By Treatment Type

• Medication
• Behavioral Therapy
• Combined Therapy

5. Attention-Deficit Hyperactivity Disorder Market, By Age Group

• Children
• Adults

6. Attention-Deficit Hyperactivity Disorder Market, By Subtypes of ADHD

• Predominantly Inattentive Presentation
• Predominantly Hyperactive-Impulsive Presentation
• Combined Presentation

7. Regional Analysis

• North America
• United States
• Canada
• Mexico
• Europe
• United Kingdom
• Germany
• France
• Italy
• Asia-Pacific
• China
• Japan
• India
• Australia
• Latin America
• Brazil
• Argentina
• Chile
• Middle East and Africa
• South Africa
• Saudi Arabia
• UAE

8. Market Dynamics

• Market Drivers
• Market Restraints
• Market Opportunities
• Impact of COVID-19 on the Market

9. Competitive Landscape

• Key Players
• Market Share Analysis

10. Company Profiles

• Eli Lilly and Company
• Pfizer Inc.
• Johnson & Johnson Services Inc.
• Lupin
• Novartis AG
• Takeda Pharmaceutical Company Limited
• Mallinckrodt plc.
• Purdue Pharma LP
• NEOS Therapeutics Inc.
• Supernus Pharmaceuticals Inc.

11. Market Outlook and Opportunities

• Emerging Technologies
• Future Market Trends
• Investment Opportunities

12. Appendix

• List of Abbreviations
• Sources and References